Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children

Vaccine

Volumn 18, Issue 1-2, 1999, Pages 82-88

  Boyce, Thomas G ^a   Gruber, William C ^a   Coleman Dockery, Shanita D ^a   Sannella, Edith C ^a   Reed, George W ^b   Wolff, Mark ^c   Wright, Peter F ^a  

^a Div Pediat Infect Dis Dept P   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c EMMES CORPORATION   (United States)

Author keywords

Intranasal influenza vaccine; Kinetic ELISA; Mucosal immunity

Indexed keywords

IMMUNOGLOBULIN A; INFLUENZA VACCINE; TRIPLE VACCINE;

ANTIBODY RESPONSE; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNITY; IMMUNOGLOBULIN PRODUCTION; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INTRANASAL DRUG ADMINISTRATION; MUCOSA; PRESCHOOL CHILD; PRIORITY JOURNAL; VIRUS ATTENUATION;

ADMINISTRATION, INTRANASAL; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; INFANT; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE; SENSITIVITY AND SPECIFICITY; VACCINES, ATTENUATED;

EID: 0033588421     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00183-8     Document Type: Article

References (20)

1. Glezen W.P., Couch R.B. Interpandemic influenza in the Houston area, 1974-1976. N Engl J Med. 298:1978;587-592.
2. Gruber W.C., Taber L.H., Glezen W.P., Clover R.D., Abell T.D., Demmler R.W., Couch R.B. Live attenuated and inactivated influenza vaccine in school-age children. Am J Dis Child. 144:1990;595-600.
3. Edwards K.M., Dupont W.D., Westrich M.K., Plummer W.D. Jr., Palmer P.S., Wright P.F. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis. 169:1994;68-76.
4. Clover R.D., Crawford S., Glezen W.P., Taber L.H., Matson C.C., Couch R.B. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J Infect Dis. 163:1991;300-304.
5. Sugaya N., Nerome K., Ishida M., Matsumoto M., Mitamura K., Nirasawa M. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. JAMA. 272:1994;1122-1126.
6. Keitel W A., Cate T.R., Couch R.B. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am J Epidemiol. 127:1988;353-364.
7. Wright P.F., Cherry J.D., Foy H.M., Glezen W.P., Hall C.B., McIntosh K., Monto A.S., Parrott R.H., Portnoy B., Taber L.H. Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children: a multicentered evaluation of dosage and safety. Rev Infect Dis. 5:1983;758-764.
8. Boyer K.M., Cherry J.D., Wright P.F., Lerman S.J., Gross P.A., Foy H.M., Taylor J.W., Noble G R. Clinical reactions and serologic responses in healthy children aged six to 35 months after two-dose regimens of inactivated A/New Jersey/76 influenza virus vaccines. J Infect Dis. 136:1977;S579-S583.
9. Monto A.S., Davenport F.M., Napier J.A., Francis T. Jr. Modification of an outbreak of influenza in Tecumseh, MI by vaccination of schoolchildren. J Infect Dis. 122:1970;16-25.
10. Maassab H.F. Biologic and immunologic characteristics of cold-adapted influenza virus. J Immunol. 102:1969;728-732.
11. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., Bernstein D.I., Hayden F G., Kotloff K., Zangwill K., Iacuzio D., Wolff M. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 338:1998;1405-1412.
12. Johnson P.R., Feldman S., Thompson J.M., Mahoney J.D., Wright P.F. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis. 154:1986;121-127.
13. Snyder M H., Banks S., Murphy B.R. Determination of antibody response to influenza virus surface glycoproteins by kinetic enzyme-linked immunosorbent assay. J Clin Microbiol. 26:1988;2034-2040.
14. SAS v. 6.12. Cary, NC, SAS Institute, 1996.
15. Thompson J., Pham D.M., Werkaven J.A., Sannella E., Ikizler M., Wright P.F. Optimal collection and assay of upper respiratory specimens for determination of mucosal immune responses to influenza. Brown L.E., Hampson A.W., Webster R.G. Options for the control of influenza III. 1996;263-270 Elsevier, Amsterdam.
16. Smith C.B., Purcell R.H., Bellanti J.A., Chanock R.M. Protective effect of antibody to parainfluenza type 1 virus. N Engl J Med. 275:1966;1145-1152.
17. Feldman S., Wright P.F., Webster R.G., Roberson P.K., Mahoney J., Thompson J., Doolittle M., Lott L., Johnson P., Christoph R.C. Use of influenza A virus vaccines in seronegative children: live cold-adapted versus inactivated whole virus. J Infect Dis. 152:1985;1212-1218.
18. Johnson P.R. Jr., Feldman S., Thompson J.M., Mahoney J.D., Wright P.F. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated or inactivated influenza A vaccine. J Med Virol. 17:1985;325-335.
19. King J.C. Jr., Gross P.A., Denning C.R., Gaerlan P.F., Wright P.F., Quinnan G.V. Jr. Comparison of live and inactivated influenza vaccine in high risk children. Vaccine. 5:1987;234-238.
20. Tomoda T., Morita H., Kurashige T., Maassab H.F. Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response. Vaccine. 13:1995;182-190.